- Conditions
- Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma
- Interventions
- BXCL701 plus Pembrolizumab, BXCL701 monotherapy
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 9:41 PM EDT